EBIT Margin: Earnings before interest and taxes as a portion of total revenues. Calculated as: EBIT / Total Revenues
Entrada Therapeutics, Inc. (TRDA) had EBIT Margin of -621.13% for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$25.42M |
|
$-143.75M |
|
-- |
|
$25.42M |
|
$183.32M |
|
$-157.90M |
|
$15.07M |
|
$-142.83M |
|
$-142.83M |
|
$-143.75M |
|
$-143.75M |
|
$-143.75M |
|
$-143.75M |
|
$-157.90M |
|
$-157.47M |
|
41.37M |
|
41.37M |
|
$-3.47 |
|
$-3.47 |
|
| Balance Sheet Financials | |
$306.25M |
|
$7.31M |
|
$71.13M |
|
$377.38M |
|
$24.45M |
|
-- |
|
$46.79M |
|
$71.25M |
|
$306.13M |
|
$306.13M |
|
$306.13M |
|
37.59M |
|
| Cash Flow Statement Financials | |
$-128.51M |
|
$116.81M |
|
$0.89M |
|
$105.16M |
|
$94.34M |
|
$-10.82M |
|
$19.61M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
12.53 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-621.13% |
|
|
EBIT Margin |
-621.13% |
-619.46% |
|
-561.84% |
|
-565.48% |
|
$-129.55M |
|
-- |
|
-- |
|
-- |
|
0.07 |
|
-- |
|
21.60 |
|
16.90 |
|
-46.96% |
|
-46.96% |
|
-38.09% |
|
-46.96% |
|
$8.14 |
|
$-3.13 |
|
$-3.11 |
|